Other analysts have also recently issued reports about the company. Jefferies Group cut Ignyta from a buy rating to a hold rating and set a $27.00 price target for the company. in a research report on Thursday. JPMorgan Chase & Co. reiterated a buy rating and set a $20.00 price target (up from $18.00) on shares of Ignyta in a research report on Thursday, October 12th. Ladenburg Thalmann Financial Services cut Ignyta from a buy rating to a neutral rating in a research report on Tuesday, December 26th. Zacks Investment Research cut Ignyta from a buy rating to a hold rating in a research report on Wednesday, October 18th. Finally, SunTrust Banks started coverage on Ignyta in a research report on Monday, November 20th. They set a buy rating for the company. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Ignyta currently has an average rating of Hold and an average target price of $24.33.
Shares of Ignyta (NASDAQ:RXDX) opened at $26.70 on Thursday. The company has a market capitalization of $1,804.63, a P/E ratio of -9.89 and a beta of 2.09. Ignyta has a 12-month low of $4.60 and a 12-month high of $26.85. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.07 and a quick ratio of 6.07.
Several institutional investors and hedge funds have recently modified their holdings of RXDX. Numeric Investors LLC purchased a new stake in shares of Ignyta during the second quarter worth approximately $126,000. Legal & General Group Plc increased its position in shares of Ignyta by 71.9% during the second quarter. Legal & General Group Plc now owns 12,681 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 5,306 shares in the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of Ignyta during the second quarter worth approximately $132,000. Goldman Sachs Group Inc. acquired a new position in Ignyta during the first quarter worth $133,000. Finally, TD Asset Management Inc. acquired a new position in Ignyta during the second quarter worth $136,000. Hedge funds and other institutional investors own 72.86% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2018/01/01/ignyta-rxdx-pt-set-at-23-00-by-cantor-fitzgerald.html.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.